SRTAW — Strata Critical Medical, Inc.

Summary of Strata Critical Medical Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: Increased 87.4% year-over-year to $67.4 million, up from $35.9 million.
• Logistics Revenue: Grew 32.4% to $47.6 million, although it fell 3.3% sequentially from Q4 2025 due to customer mix and weather disruptions.
• Clinical Revenue: Reached $19.8 million, a 12.7% sequential increase, driven by Transplant Clinical services.
• Gross Profit: Doubled to $14.1 million, with a gross margin of 21%.
• Adjusted EBITDA: Decreased to $6.4 million from $7 million in Q4 2025, with an adjusted EBITDA margin of 9.5%.
• Operating Cash Flow: Reported at $3.9 million.
• Free Cash Flow: $2.1 million before aircraft acquisitions.
• Cash Position: Ended the quarter with $58.8 million in cash and short-term investments.

2. Strategic Updates and Business Highlights

• Acquisition: Completed the acquisition of Ohio Valley Perfusion Associates for approximately $1 million, expected to contribute $100,000 to adjusted EBITDA for the remainder of 2026.
• Expansion: Opened several new aviation bases, including a combined Logistics and Clinical base in Chicago, enhancing service capabilities in the Midwest.
• Market Position: Continued growth in the Clinical division, with strong customer acquisition in NRP (Normothermic Regional Perfusion) and Surgical Recovery services.
• M&A Strategy: Actively pursuing additional acquisitions in fragmented markets, with a robust pipeline of opportunities.

3. Forward Guidance and Outlook

• Revenue Guidance: Reiterated 2026 revenue expectations of $260 million to $275 million.
• Adjusted EBITDA Guidance: Expected between $29 million and $33 million.
• Free Cash Flow Guidance: Forecasted at $15 million to $22 million before aircraft purchases.
• Q2 Expectations: Anticipate low single-digit sequential revenue growth and an adjusted EBITDA margin improvement to approximately 10%.

4. Bad News, Challenges, or Points of Concern

• Logistics Gross Margin: Experienced a decline due to customer mix shifts towards lower-margin OPOs (Organ Procurement Organizations) and weather-related disruptions.
• Sequential EBITDA Decline: Adjusted EBITDA fell from Q4 2025, indicating potential operational challenges.
• Regulatory Scrutiny: Increased scrutiny around certification and qualification standards for donor surgeons may impose additional operational requirements and costs.
• Decreased Average Transport Distance: Noted a modest reduction in average transport distance, attributed to customer mix rather than structural changes in the market.

5. Notable Q&A Insights

• Customer Integration: High percentage of Clinical customers are also utilizing Logistics services, indicating successful cross-selling.
• Market Expansion: The new Chicago hub is expected to enhance operational efficiency and service delivery, although new customer flights are not expected until later in the year.
• Impact of Oil Prices: Fuel costs are passed through to customers, minimizing the impact on margins, although there is a focus on reducing repositioning flights to manage costs.
• Acquisition Structure: Flexible acquisition structures are being offered, often including equity components to align incentives with potential partners.
• Donor Metrics: Improvement in deceased donor activity is noted, with expectations for continued growth in the transplant sector, although this is not fully underwritten in current guidance.

This summary captures the essential financial performance, strategic initiatives, outlook, and challenges faced by Strata Critical Medical in Q1 2026, along with insights gained from the Q&A session.